Table 1. The relative risk between groups was further compared by logistic regression model Odds Ratio 95% CI p value Reoperation Small v.s. Large 1.4 1.2-1.8 0.002 Medium v.s. Large 0.9 0.7-1.1 0.23 TUIBN Small v.s. Large 6.7 2.8-16.4  0.001 Medium v.s. Large 2.9 1.2-7.2 0.02 Urethrotomy Small v.s. Large 2.2 1.7-2.9  0.001 Medium v.s. Large 1.3 1.0-1.7 0.07 Adjust with demography Factors: age, urbanized level, geographic location Source of Funding: None 1968 PVP & HOLEP VERSUS TURP DUE TO BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW AND META-ANALYSIS Sam Farah*, Matthew Winter, Nieroshan Rajarubendra, David Dyer, Trung Pham, Sree Appu, Melbourne, Australia; Dan Spernat, Woodville, Australia INTRODUCTION AND OBJECTIVES: Laser prostatectomy is an increasingly popular option for the management of benign prostatic hyperplasia (BPH). Photoselective vaporisation (PVP) and Holmium Laser Enucleation of the Prostate (HoLEP) are the two most popular laser systems. Therefore, we have conducted a systematic review and meta-analysis of PVP vs TURP and HoLEP vs TURP, to explore whether any differences in outcomes between the two exist. A further sub-group analysis was conducted between the two methods of PVP (120W LBO and 80W KTP). METHODS: Publications between 2000 and 2012 in Medline, Embase, PubMed, Cochrane Central Register of Controlled Trials were identified, as well as those found by hand searching. The risk ratio and mean difference (as well as the 95% confidence intervals) for outcomes were calculated. RESULTS: 15 trials with 2107 participants met the inclusion crite- ria with a mean follow up of 16 months. PVP and HoLEP provided similar functional outcomes (QMax and IPSS) as TURP, but have advantages in terms of hospital stay and haemostasis. Operating time with the 120W is shorter than the 80W PVP laser; however the reoperation rate is higher. CONCLUSIONS: This is the largest analysis conducted to date that reviews these two lasers. TURP, PVP and HoLEP produce similar post-operative functional outcomes. However, PVP and HoLEP offer shorter length of stay and improved haemostasis, at the cost of in- creased operating time and in some instances reoperation. PVP ben- efits from a shorter learning curve compared with HoLEP, but was associated with a higher reoperation rate when compared to TURP. Source of Funding: None 1969 A REVIEW OF GREENLIGHT LASER PROSTATECTOMY FOR BPH: CORRELATION BETWEEN ENERGY USED AND OUTCOMES Lina Carmona Echeverria*, Ben Williamson, Alastair Dick, Gordon H Muir, London, United Kingdom INTRODUCTION AND OBJECTIVES: We hypothesised that greater energy use per unit of prostate volume (relative energy) might improve the outcomes of GreenLight™ prostate vaporisation by caus- ing a more complete prostate cavity. A meta-analysis was performed to assess energy use and prostate volume with intermediate term clinical efficacy, complications and re-operation rate. METHODS: An electronic search (MEDLINE) was carried out to identify publications in the English language between 2003-2011. Us- ing an evidence-based approach, our search focused on the highest quality studies from randomized clinical trials and case studies. We recorded patient age, GreenLight™ power, prostate volume, energy used, pre and postoperative IPSS, QoL, flow rate, post void residual (PVR), retention rate, maximum follow up (f/u) and complications. Multivariate analysis was performed using SPSS. RESULTS: 48 studies were found. 20 were excluded due to lack of data collected (ie energy used, prostate size). 80 W and 120 W lasers were included. Outcome data and demographics are shown in table 1. The quality of reporting varied widely, 1 year f/u was very variable from 100% down to only 35%. Complications were low apart from a variable rate of reported dysuria Multivariate analysis shows that relative energy use (kJ/cm3) increased with time (1.63 in 2003 to 3.13 in 2010.) Overall 1 year reoperation rate was 2.9% (0-13.3%). There was no relation between prostate size or energy use and complication rates. Postoperative prostate size and PSA reduction were poorly reported. There was a trend to greater improvements with IPSS with increasing energy, but no other parameters showed a link. The great variability of relative energy used, and the presence of several major outlying studies relating to re-operation rates, made analysis difficult. Those studies which did not report energy use tended to have the poorest outcomes in this respect. The presence of several outlying studies in terms of dysuria and re-operation rates would suggest issues with technique. CONCLUSIONS: GreenLight prostate vaporisation is safe and effective. It should be a simple operation to standardise, yet the data here suggest the reverse is true. Studies which do not report amount of energy used have the worst re-operation rates. Future studies must aim to standardise both technique and reporting quality. Demographics value (SD) Range Age 69 years (7.5) 51-87 years Prostate Volume 63 (23.6) 37-154 Anticoagulation 30 % 0 - 100 % Preoperative (SD) Postoperative (SD) Qmax 7.8 ml/sec (3.1) 20.4 ml/sec (7.6) PVR 146 ml (122) 29.5 ml (40.9) IPSS 21.2 (5.8) 6.59 (4.06) QoL 4.22 (1.0) 1.1 (0.94) Source of Funding: None 1970 A PROSPECTIVE MULTICENTER RANDOMIZED STUDY COMPARING GREENLIGHT XPS™ LASER AND TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (GOLIATH): PRELIMINARY PERIOPERATIVE OUTCOME DATA Alexander Bachmann*, Basel, Switzerland; Andrea Tubaro, Rome, Italy; Neil Barber, Camberley Surrey, United Kingdom; Frank D’Ancona, Nijmegen, Netherlands; Gordon Muir, London, United Kingdom; Ulrich Witzsch, Frankfurt, Germany; Marc-Oliver Grimm, Jena, Germany; Joan Benejam, Manacor, Spain; Jens-Uwe Stolzenburg, Leipzig, Germany; Anthony Riddick, Edinburgh, United Kingdom; Sascha Pahernik, Heidelberg, Germany; Herman Roelink, Almelo, Netherlands; Filip Ameye, Gent, Belgium; Andrew Thomas on behalf of the GOLIATH Investigators, Bridgend, United Kingdom INTRODUCTION AND OBJECTIVES: The objective of this prospective randomized trial was to assess the efficacy and safety of GreenLight XPS™ 180-W laser (PVP) compared with transurethral resection of the prostate (TURP) in subjects with lower urinary tract symptoms secondary to benign prostatic hyperplasia. METHODS: 292 subjects have been enrolled at 29 sites in 11 European countries. After being treated with TURP or PVP, a variety of surgical, recovery and symptomatic variables (IPSS, etc.) were assessed. Several objective outcome parameters were evaluated, including Qmax, PVR, PSA, prostate volume reduction and incidence of complications. RESULTS: 292 subjects were enrolled between April 2011 and September 2012; of which 276 randomized (136 PVP, 140 TURP). 263 subjects received treatment (134 PVP, 129 TURP) with 204 subjects e808 THE JOURNAL OF UROLOGY Vol. 189, No. 4S, Supplement, Tuesday, May 7, 2013